OpenNashPodcasts

Person

Sue Desmond-Hellmann

Sue Desmond-Hellmann is a physician and biotech leader who spoke on The Long Run with Luke Timmerman (Ep95) about her path from a Reno childhood to cancer medicine, AIDS research and drug development at Genentech. She describes her family's drugstore, strict Catholic schooling, and switching from sports medicine to oncology.

She also recalls treating Kaposi's sarcoma patients at UCSF in the 1980s and going to Uganda to study HIV transmission. She says Genentech had no cancer drugs when she joined in the mid-1990s, and that she vividly remembers the day Herceptin was approved.

1 episodes · 19 quoted claims

Desmond-Hellmann's family moved from Napa to Reno when she was one, and her father and a partner opened a privately owned drugstore there.

“my parents moved to Reno. Reno was really small then and really Western and different and a new town. And my dad and his partner opened up a privately owned drugstore.”

The Long Run with Luke Timmerman · 0:09:31

Desmond-Hellmann attended Catholic school for 12 years and describes her parents as extremely strict.

“I went to Catholic school for 12 years. My parents were extremely strict.”

The Long Run with Luke Timmerman · 0:10:13

Desmond-Hellmann was the second of seven children, and the youngest was born the summer after she finished high school.

“The youngest in my family was born the summer after I finished high school.”

The Long Run with Luke Timmerman · 0:11:55

Desmond-Hellmann attended the University of Nevada for college and medical school while living at home, to keep expenses low.

“A couple miles away from our house. I lived at home and was so close to running out of money by the time medical school was over.”

The Long Run with Luke Timmerman · 0:18:15

Working with oncologist Dr. Stephen Hall in Reno during clinical rotations led Desmond-Hellmann to switch from sports medicine to oncology.

“When I started on the clinical rotations, I worked with a physician, Dr. Stephen Hall, an oncologist in Reno.”

The Long Run with Luke Timmerman · 0:21:17

In 1982 UCSF's internal medicine department accepted a trainee from the University of Nevada for the first time, Desmond-Hellmann.

“UCSF, for the first time ever in their internal medicine department, took a kid from University of Nevada.”

The Long Run with Luke Timmerman · 0:27:14

AIDS was first described in 1981, and Desmond-Hellmann began internship at UCSF in 1982, as the epidemic hit gay men in San Francisco.

“So HIV AIDS is described in 81. And I hit San Francisco as an intern in 82.”

The Long Run with Luke Timmerman · 0:27:55

Nick Hellman, from the University of Kentucky, trained at UCSF alongside Desmond-Hellmann and became her best friend and later partner.

“UCSF also took another kid from a state school from University of Kentucky, Nick Hellman, who became my best friend as an intern.”

The Long Run with Luke Timmerman · 0:28:41

About three years into her training, Desmond-Hellmann moved into the AIDS clinic at UCSF and treated Kaposi's sarcoma patients full time.

“by the time I was three years into my training, I actually moved into the AIDS clinic and started taking care of Kaposi's sarcoma patients full time.”

The Long Run with Luke Timmerman · 0:29:29

Kaposi's sarcoma had previously been a rare cancer in elderly Mediterranean men, but in AIDS patients with low CD4 cells it showed how the immune system fights off cancer.

“But here, as these patients had low CD4 cells and immune systems that weren't right, some came with pneumocystis cariniae pneumonia or fungal infections or other infectious diseases, but some presented with Kaposi sarcoma.”

The Long Run with Luke Timmerman · 0:30:34

Desmond-Hellmann and Nick Hellman went to Uganda on a Rockefeller Foundation-funded project to study heterosexual HIV transmission.

“Nick and I went to study heterosexual transmission of HIV in a Rockefeller Foundation-funded project during the AIDS epidemic.”

The Long Run with Luke Timmerman · 0:33:04

After returning from Uganda, Desmond-Hellmann practiced as an oncologist for about two years and passed her oncology boards.

“As I like to say now, I was a real doctor for two years, a practicing oncologist. I took my boards, passed my oncology boards.”

The Long Run with Luke Timmerman · 0:37:41

Nick Hellman was recruited to Bristol-Myers Squibb to work on an early antiretroviral drug, which took the couple to Connecticut.

“And then Nick got recruited to Bristol-Myers Squibb to work on D14, one of the first antiretroviral drugs.”

The Long Run with Luke Timmerman · 0:37:41

When Desmond-Hellmann joined in the mid-1990s, Genentech had three approved drugs: growth hormone, Activase and Pulmozyme, and no cancer drugs.

“Genentech had three approved drugs, growth hormone, Activase, and Pulmozyme.”

The Long Run with Luke Timmerman · 0:41:42

Desmond-Hellmann notes Genentech was founded in 1976 and that she arrived almost 20 years later.

“And the fact was that Genentech was founded in 76. So I got there, you know, almost 20 years later.”

The Long Run with Luke Timmerman · 0:44:51

Genentech's partnership with IDEC on Rituxan came around 1995 or 1996, and Rituxan was approved in 1997.

“There was not. The partnership came, I think, in 95, 96, because Rituxan was approved in 97.”

The Long Run with Luke Timmerman · 0:45:56

Desmond-Hellmann says Genentech worked with IDEC on Rituxan's approval, and that Herceptin was harder because a diagnostic test had to be approved along with the drug.

“with IDEC, with Antonio Rio Lopez, we worked on the approval of Rituxan, which was hard, but then Herceptin, which was massively hard because we had to get the therapeutic and the diagnostic.”

The Long Run with Luke Timmerman · 0:46:33

Genentech's R&D head Art Levinson believed in leaving a job open rather than hiring a 'B minus', which made rapid growth harder.

“Art had this philosophy that if you couldn't find the right person for the job, you should just leave it open.”

The Long Run with Luke Timmerman · 0:48:54

Desmond-Hellmann says she vividly remembers the day Herceptin was approved and thinking of the women it would help.

“I tell people that when the day that Herceptin was approved, I still remember like it was yesterday.”

The Long Run with Luke Timmerman · 0:56:41